Four studies evaluating effectiveness, trends and other considerations for active surveillance in managing prostate cancer were presented during the 110th annual scientific meeting of the American Urological Association (AUA). Stacy Loeb, M.D., assistant professor of urology at New York University, moderated the session.

IBA (Ion Beam Applications S.A.) announced the successful completion of its fifth IBA Academy on the Road enhanced training workshop. This, and several other training offerings, are key cornerstones of the IBA CAREprogram initiative, which allows close partnering with IBA customers for optimized user satisfaction.

IBA Academy on the Road

The prostate-specific membrane antigen (PSMA) biomarker is the bullseye for three new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of tumor types. The agents were discussed in research unveiled at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Royal Philips announced the introduction of HeartModelA.I., a new Anatomically Intelligent Ultrasound (AIUS) tool that brings advanced quantification, automated 3-D views and robust reproducibility to cardiac ultrasound imaging. Philips' fastest 3-D AIUS ultrasound measurement method was unveiled on its Epiq 7 ultrasound system during the American Society of Echocardiography (ASE) annual meeting in Boston.

Researchers announced the results of a study to develop and validate a model, comprised of echocardiographic and clinical data, to predict three-year mortality of patients hospitalized in coronary care units (CCU). The results describe an integrated score for three-year mortality of CCU patients, comprised of fewer variables and better/equal predictive value compared to existing scores.

A research team from New York has announced advances in automated echocardiography decision systems that could help clinicians more accurately assess complex heart disease. The team developed a system that takes a large amount of information from ultrasound images, learns about the structure and function of the heart, and automatically differentiates enlarged hearts seen in patients with hypertrophic cardiomyopathy (HCM) from a normal variation of enlarged hearts seen in athletes. The two conditions are often difficult to distinguish from each other, and misdiagnoses might have major implications, since undiagnosed HCM is one of the most common causes of sudden cardiac death in athletes, while thickening seen in athlete's heart is benign and does not generally lead to dysfunction.

Researchers announced results of a new study which demonstrated that smartphone-based mHealth devices, coupled with handheld echocardiography, can provide improved assessment and are readily integrated at the point-of-care for evaluation of patients with structural heart diseases. This study was conducted as part of the American Society of Echocardiography (ASE) Foundation’s Valvular Assessment Leading to Unexplored Echocardiographic Stratagems (VALUES) program, a four-day teaching and research event held at the Sri Sathya Sai Institute of Higher Medical Sciences in Bangalore, India, August 11-14, 2014. Over the course of several days, researchers assessed patients with multiple forms of rheumatic valvular heart disease with either standard diagnostic equipment or mobile health-based devices.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now